v3.25.2
Segment Information (Tables)
3 Months Ended
Jul. 31, 2025
Segment Reporting [Abstract]  
Summary of Selected Financial Information with Respect to Single Operating Segment

The following table presents selected financial information with respect to the Company’s single operating segment for the three months ended July 31, 2025 and 2024 (in thousands):

 

 

Three Months Ended

 

 

July 31,

 

 

2025

 

 

2024

Product revenue, net

$

1,426

 

$

Operating expenses:

 

 

 

 

 

Cost of revenue

 

590

 

 

Clinical development

 

7,791

 

 

14,449

Research

 

10,329

 

 

10,560

Regulatory & QA

 

2,196

 

 

1,605

Pre-commercial planning

 

27,088

 

 

10,651

Other SG&A

 

12,441

 

 

6,950

Total operating expenses

 

60,435

 

 

44,215

(Loss) income from operations

 

(59,009)

 

 

(44,215)

Other income

 

1,070

 

 

3,772

(Loss) income before income taxes

$

(57,939)

 

$

(40,443)

Provision for (benefit from) for income taxes

 

2,157

 

 

Net loss

$

(60,096)

 

$

(40,443)